Channel Therapeutics Corporation
CHROAMEXHealthcare
$1.35
+$0.09(+7.14%)
Market Cap$8904398
P/E Ratio—
52W High$54.29
52W Low$1.2301
Channel Therapeutics Corporation (CHRO) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · CHRO · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $16.80M | $0.00M | $0.00M | $0.00M | $0.00M |
| Cost of Revenue | $0.00M | $0.00M | $2.58M | $0.39M | $0.21M |
| Gross Profit | $0.00M | $0.00M | ($2.58M) | ($0.39M) | ($0.21M) |
| Gross Margin %(computed) | 0.00% | — | — | — | — |
| Operating Expenses | |||||
| R&D Expenses | $1.23M | $1.18M | $2.58M | $0.39M | $0.21M |
| G&A Expenses | $0.00M | $6.39M | $4.28M | $1.93M | $0.63M |
| Total Operating Expenses | $49.23M | $7.57M | $6.86M | $2.32M | $0.84M |
| Operating Income | $0.00M | ($7.57M) | ($6.86M) | ($2.32M) | ($0.84M) |
| Operating Margin %(computed) | 0.00% | — | — | — | — |
| Interest Income | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Interest Expense | ($3.01M) | ($0.79M) | $0.52M | $0.14M | $0.00M |
| Income Before Tax | ($50.71M) | ($7.96M) | ($7.38M) | ($2.46M) | ($0.60M) |
| Income Tax Expense | ($7.39M) | $0.00M | $0.00M | $0.00M | $0.00M |
| Net Income | ($43.32M) | ($7.96M) | ($7.38M) | ($2.46M) | ($0.60M) |
| Net Margin %(computed) | -257.93% | — | — | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-23.04 | $-1.43 | $-1.28 | $-0.43 | $-0.10 |
| Wtd Avg Shares | 18.80M | 5.57M | 5.77M | 5.77M | 5.77M |
| EBITDA | $0.00M | ($7.57M) | ($6.86M) | ($1.63M) | $0.00M |
| EBITDA Margin %(computed) | 0.00% | — | — | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · USD · M
Explore more Channel Therapeutics Corporation data
About Channel Therapeutics Corporation (CHRO) Income Statement
Channel Therapeutics Corporation (CHRO) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, CHRO reported revenue of $0.02B, gross profit of $0.00B (gross margin 0.00%), and net income of ($0.04B) — a net profit margin of -257.93%.
Frequently asked questions
CHRO · 4 questionsChannel Therapeutics Corporation (CHRO) reported revenue of $0.02B for 2025, up —% year-over-year.
CHRO revenueCHRO salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09